Abstract：
This Viewpoint discusses a recent federal court decision that invaliated the Food and Drug Administration’s (FDA) approval of mifepristone, a drug used to end pregnancies and manage miscarriage when used with misoprostol, and how that decision challenges the legitimacy and independence of the FDA.
摘要：
本观点讨论了最近联邦法院的一项裁决，该裁决使美国食品和药物管理局（FDA）对米非司酮的批准无效，与米索前列醇一起使用时用于终止妊娠和控制流产的药物，以及该决定如何挑战FDA的合法性和独立性。
